For research use only. Not for therapeutic Use.
JAK-IN-26 (CAT: I040920 is an orally active inhibitor targeting Janus kinases (JAK), with favorable pharmacokinetic properties. It inhibits the phosphorylation of STAT3, a downstream signaling molecule in the JAK-STAT pathway, in response to IFN-α2B stimulation in Jurkat cells (IC50 = 17.2 nM). The JAK-STAT signaling pathway is crucial in immune response regulation and is often dysregulated in autoimmune diseases and cancers. By inhibiting JAK, JAK-IN-26 can suppress aberrant immune signaling. This compound is particularly relevant for Inflammation & Immunology Research, offering a potential therapeutic strategy for autoimmune diseases and immune-related cancer therapies.
| CAS Number | 2417134-93-9 |
| Synonyms | N-[4-[2-methoxy-3-(1-methyl-1,2,4-triazol-3-yl)anilino]-5-propanoylpyridin-2-yl]cyclopropanecarboxamide |
| Molecular Formula | C22H24N6O3 |
| Purity | ≥95% |
| IUPAC Name | N-[4-[2-methoxy-3-(1-methyl-1,2,4-triazol-3-yl)anilino]-5-propanoylpyridin-2-yl]cyclopropanecarboxamide |
| InChI | InChI=1S/C22H24N6O3/c1-4-18(29)15-11-23-19(26-22(30)13-8-9-13)10-17(15)25-16-7-5-6-14(20(16)31-3)21-24-12-28(2)27-21/h5-7,10-13H,4,8-9H2,1-3H3,(H2,23,25,26,30) |
| InChIKey | FKCATCQHVCOBCX-UHFFFAOYSA-N |
| SMILES | CCC(=O)C1=CN=C(C=C1NC2=CC=CC(=C2OC)C3=NN(C=N3)C)NC(=O)C4CC4 |
